Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Drug Industry Worries Whether New Pricing Policy Robust Enough

This article was originally published in PharmAsia News

Executive Summary

Some of the largest brands are faced with losing their sheen as debate heats up in the drug industry over whether the new Indian drug pricing system is robust enough to deliver needed reform.

Advertisement

Related Content

Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC079605

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel